Terumo Aortic today announced that it has received the King’s Award for Enterprise in the Innovation category for its bespoke solutions for the treatment of complex aortic disease using a combination of surgical and endovascular technologies.
The award particularly recognises the innovation behind the Thoracoflo and custom Thoraflex Hybrid devices. This is the company’s second King’s Award for Enterprise, having previously been the recipient of one King’s Award and eight Queen’s Awards.
A press release details that the innovation lies in expanding Terumo Aortic’s custom solutions programme (subject to local regulatory approval) to include hybrid aortic technologies. The company notes that this approach enables clinicians to treat complex aortic diseases, such as thoracoabdominal aortic aneurysms and complex aortic dissections, with tailored hybrid solutions.
Commenting on this success, Erik Pomp, executive vice president and chief operating officer of Terumo Aortic, said: “We are honoured to have received this highly prestigious award which recognises our ongoing commitment to advancing aortic care. By continuously evolving our product portfolio, embracing hybrid approaches, and working in close collaboration with specialist clinicians, we are enabling improved patient outcomes. This innovation addresses the growing need for more adaptable, comprehensive solutions in the treatment of complex aortic pathology.”
The King’s Awards for Enterprise represent the highest honour for businesses and individuals in the UK and recognise outstanding achievements by UK businesses in the fields of innovation, international trade and sustainable development.
